A meta-analysis of PON3 showed that PON3 is downregulated not only in HCC, but also in clear cell sarcomas of the kidney, ovarian serous papillary carcinomas, cervical carcinomas, papillary thyroid carcinomas, prostate carcinomas, and non-Hodgkin’s lymphoma while PON3 was upregulated in lung adenocarcinoma and pancreatic carcinoma [98]. The gene discussed is PON3; the disease is non-Hodgkin lymphoma.